Bill
S 805
Massachusetts requires routine PANDAS/PANS screening for children; DPH to publish criteria, standards, and regs, with clinicians and facilities required to screen.
Status: SIGNED — Chapter 131 (enacted 2025-05-23)
Filed: 01/17/2025; Introduced: 02/27/2025 (Senate)
Primary filer/petitioners in bill text: Senator Patrick M. O’Connor; co‑petitioner Joan B. Lovely
Note on metadata: some accompanying metadata in the file appears inconsistent (lists several U.S. Senators and federal bill numbers). The text of S.805 is a Massachusetts state law establishing screening requirements and regulatory duties related to PANDAS/PANS.
Purpose
- To require routine screening for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute‑onset neuropsychiatric syndrome (PANS) in medical/clinical settings that serve children, and to direct the Department of Public Health (DPH) to develop working criteria, best‑practice standards, and implementing regulations.
Key provisions
- New program and standards (Chapter 111 — inserted section 242A)
- DPH must establish a screening program for PANDAS/PANS for all children.
- DPH will convene a medical professional consortium to research and publish best practice standards for diagnosis and treatment that are evidence‑based and accessible to clinicians.
- PANS working criteria (in section 242A(b))
- Defines a clinically distinct PANS presentation requiring:
1. Abrupt, dramatic onset of obsessive‑compulsive disorder (OCD) or severely restricted food intake; and
2. Concurrent acute onset of at least two additional neuropsychiatric symptom categories from: anxiety; emotional lability/depression; irritability/aggression/severe oppositional behavior; behavioral or developmental regression; deterioration in school performance related to ADHD‑like symptoms, memory or cognitive changes; sensory or motor abnormalities; somatic signs (sleep disturbance, enuresis/urinary frequency); and
3. Symptoms not better explained by a known neurologic or medical disorder (e.g., Sydenham chorea).
- Provider screening requirements (Chapter 112 — inserted section 12HH)
- Physicians (various license categories), licensed child psychiatrists/psychologists, licensed certified social workers, and licensed mental health counselors must screen patients for PANDAS/PANS at intervals and by methods specified in DPH regulations.
- Hospitals, clinics, HMOs and other health care facilities serving children must take steps to ensure patients receive such screening.
- Statutory edits to insurance/coverage language
- Minor text insertions in multiple chapters (32A, 175, 176A, 176B, 176G) add the words “screening and” to existing statutory phrases — indicating screening is to be treated within the scope of covered services/benefit language referenced in those chapters.
- Implementation timeline
- DPH must promulgate working criteria and implementing regulations within 180 days of the act’s effective date.
- The provider screening requirement (Section 3 / Chapter 112 §12HH) becomes effective 270 days after the effective date of the act.
Who is affected
- Primary: children (pediatric patients) in Massachusetts, particularly those presenting with abrupt neuropsychiatric symptoms.
- Clinical providers: physicians (various licensure categories), psychiatrists, psychologists, social workers, mental health counselors — who will be required to screen per DPH rules.
- Health care facilities and HMOs: responsible for ensuring screening occurs.
- Payers/insurers: statutory edits suggest screening may be recognized within coverage frameworks; practical effects on reimbursement will depend on DPH regulations and insurer implementation.
Potential impacts and considerations
- Earlier identification and referral for PANDAS/PANS could improve access to appropriate care and standardize diagnostic approaches across providers.
- Compliance will require new screening protocols, clinician training, and administrative changes at facilities and insurers.
- The quality and scope of screening, referral, and treatment pathways will hinge on the DPH consortium’s published best practices and the content of regulations issued within the 180‑day window.
Procedural notes
- The act was passed by the Massachusetts Legislature and signed into law as Chapter 131 on May 23, 2025.
- Regulations and the effective date for provider obligations are tied to that enactment date (180‑ and 270‑day deadlines specified).
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
